Daratumumab and hyaluronidase-fihj plus pomalidomide and dexamethasone have been approved by the FDA for the treatment of multiple myeloma

Share This Post

August 2021: Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) have been approved by the Food and Drug Administration in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy that included lenalidomide and a proteasome inhibitor.

In APOLLO (NCT03180736), 304 patients were randomised (1:1) to Darzalex Faspro with pomalidomide and dexamethasone (Pd) against Pd alone in an open-label, active-controlled trial. Patients were given Darzalex Faspro 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) subcutaneously once weekly from Weeks 1 to 8, once every 2 weeks from Weeks 9 to 24, and once every 4 weeks starting with Week 25 until disease progression or unacceptable toxicity, along with pomalidomide 4 mg once daily orally on days 1-21 of each 28-day cycle; and dexamethasone 40 mg once daily or

The primary effectiveness metric was progression-free survival (PFS). The median PFS in the Darzalex Faspro-Pd therapy group was 12.4 months compared to 6.9 months in the Pd treatment group (HR 0.63; 95 percent CI: 0.47, 0.85; p=0.0018), indicating a 37 percent lower risk of disease progression or mortality in patients treated with Darzalex Faspro-Pd versus Pd.

Fatigue, pneumonia, upper respiratory tract infection, and diarrhoea are the most prevalent adverse events in individuals with multiple myeloma who received Darzalex Faspro-Pd (20%).

Darzalex Faspro’s recommended dosage is 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) injected subcutaneously into the abdomen over 3 to 5 minutes according to the manufacturer’s instructions.

Reference: https://www.fda.gov/

Check details here.

 

Take second opinion on multiple myeloma treatment

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Polatuzumab
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

https://cancerfax.com/